There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), BellRing Brands (BRBR – Research Report) and Optinose (OPTN – Research Report) with bullish sentiments.
Regeneron (REGN)
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Regeneron today and set a price target of $780.00. The company’s shares closed last Friday at $622.96.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $706.80 average price target, implying a 15.9% upside from current levels. In a report issued on January 31, Truist Financial also maintained a Buy rating on the stock with a $754.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
BellRing Brands (BRBR)
In a report released today, Kenneth Zaslow from BMO Capital maintained a Buy rating on BellRing Brands, with a price target of $33.00. The company’s shares closed last Friday at $23.01.
According to TipRanks.com, Zaslow is a 5-star analyst with an average return of
Currently, the analyst consensus on BellRing Brands is a Strong Buy with an average price target of $31.63, representing a 31.2% upside. In a report issued on January 26, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $33.00 price target.
Optinose (OPTN)
In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Optinose, with a price target of $9.00. The company’s shares closed last Friday at $2.41.
According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Optinose is a Strong Buy with an average price target of $9.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
